Use cases

In the pages below, we present a sampling of use cases that address customer challenges with developing and bringing mental health treatments to market.

| Use Case

Compare effectiveness of treatment for Major Depressive Disorder

Challenge

There is a lack of standardized depression outcomes for comparisons of effectiveness among antidepressants in the real world.

Solution

Leveraged EMR + PRO data from 23 million outpatient encounters focused on mental health
Identified differences in outcomes for specific patient types with PHQ-9 scores

12.3 million patients with MDD
412,000 patients with EMR notes
1 million patients with PHQ-9
250,000 patients on SSRIs

| Use Case

Response to treatment with second generation antipsychotics

Objectives

Evaluate the side-effects (including weight gain and other risk factors) and costs associated with use of second generation antipsychotics.
Evaluate patterns of select adverse effects and associated outcomes across pre-defined populations

Solution

Results

Identified patients at higher risk for treatment-associated adverse clinical outcomes and higher costs

128,000+ patients followed longitudinally with deep clinical data

| Use Case

Prediction of Treatment Resistant Depression

Challenge

For healthcare providers and payers alike, identifying patients at high risk for developing treatment resistant depression (TRD) can inform case management

Solution

OM1 has developed an AI model to identify patients at high risk for TRD, allowing for earlier, more effective intervention.

PhenOM^TM identifies patients at elevated risk for high healthcare resource utilization associated with treatment resistance.

| Use Case

Measure impact of depression in Rheumatoid Arthritis

Challenge

Depression impacts the effectiveness of rheumatoid arthritis (RA) treatments, raising costs and the complexity of care for these patients.

Solution

Disease activity scores of RA patients diagnosed with depression were compared to scores of those without
Clinical outcomes of RA patients diagnosed with depression who initiated antidepressant treatment were compared to those who did not

120,000+ pts followed longitudinally with deep clinical data